L.E.K.
Stephen Sunderland
PartnerLansen Pharmaceutical Holdings Limited
Dong Sheng
BD ManagerLeibniz-Institut fuer Analytische Wissenschaften - ISAS
Suyuan Chen
Research associateLEO Pharma
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.
We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.
LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.
LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.
Rachit Vohra
Business Development DirectorLibera Bio
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Olivier Jarry
CEOLuoxin Pharma
Angelina Zhang
BD DirectorLuye Pharma
Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others.
Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.